Abstract 1386P
Background
MET gene amplification is a potential therapeutic target in lung adenocarcinoma (LUAD) currently identified by fluorescence in situ hybridization (FISH). Next-generation sequencing (NGS) has become an essential diagnostic tool for routine biomarker profiling of cancer patients, including the detection of copy number alterations (CNAs). The aim of this study was to evaluate the concordance between these two methods and identify potential limitations of NGS implementation.
Methods
Thirty cases with MET amplification detected by FISH were retrospectively selected from a cohort of 567 LUAD diagnosed between 2018 and 2022 (prevalence: 5.3%). Cases were classified according to the current Camidge-2021 FISH criteria as 5 low-amplified (MET/CEP7 ratio ≥1.8 to ≤2.2), 11 medium-amplified (MET/CEP7 ratio >2.2 to <4) and 14 high-amplified (MET/CEP7 ratio ≥4). Tumor area and tumor cell percentage were annotated to later evaluate complete molecular alterations by NGS using the Oncomine Precision Assay.
Results
Detection of MET amplification was concordant in only 16 out of 30 cases (5 cases were excluded due to insufficient DNA), and no correlation was found between MET copy number determined by FISH and NGS (R2=0.346). Distribution of amplification categories was random: 2 cases showed low-amplification, 7 medium-amplification, and 7 high-amplification. Slight differences were observed between concordant and discordant cases in: MET enumeration (12.4 vs. 9.3 gene copies), MET/CEP7 ratio (4.8 vs. 3.2), tumor area (15 vs. 11mm2), and DNA concentration (12 vs. 7 ng/μl), but none of them were statistically significant. FISH results of the 9 discordant cases were reviewed and high copy number heterogeneity was observed in 7 of them and focal amplifications were observed in 2. In 7 out of 9 discordant cases, co-alterations were detected: 2 KRAS (p.G12C and p.Q61H), 2 BRAF non-V600, 2 MET exon 14 skipping and one EGFR p.L858R.
Conclusions
The detection of MET amplification by NGS did not show satisfactory concordance with the results obtained by FISH, likely due to the high heterogeneity in MET gene copy number enumeration. As a result, complementary determination by FISH is necessary, given the lack of standardized criteria for establishing CNAs positivity by NGS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1391P - Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Presenter: Oscar Jose Juan Vidal
Session: Poster session 20
1392P - Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
Presenter: Karlijn Verkerk
Session: Poster session 20
1393P - Characteristics of MET gene and its relationship with TMB/MMR genes in Chinese NSCLC population
Presenter: Hong Yi Zhang
Session: Poster session 20
1394P - Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
Presenter: Urska Janzic
Session: Poster session 20
1396P - HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
Presenter: Didier Debieuvre
Session: Poster session 20
1397P - Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort
Presenter: Jair Bar
Session: Poster session 20
1398P - Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
Presenter: Sophie Ernst
Session: Poster session 20
1399P - Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer
Presenter: Joshua Reuss
Session: Poster session 20
1400P - Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Presenter: Marie Wislez
Session: Poster session 20
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20